Chen Jenny T, Bonneau Laura A, Weigel Tracey L, Maloney James D, Castro Francisco, Shulzhenko Nikita, Bentz Michael L
Division of Plastic and Reconstructive Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis; Maine Medical Center, Cardiothoracic Surgery, Portland, Maine; and Division of Thoracic Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Plast Reconstr Surg Glob Open. 2016 Mar 17;4(3):e638. doi: 10.1097/GOX.0000000000000603. eCollection 2016 Mar.
We describe the second largest contemporary series of flaps used in thoracic reconstruction.
A retrospective review of patients undergoing thoracomyoplasty from 2001 to 2013 was conducted. Ninety-one consecutive patients were identified.
Thoracomyoplasty was performed for 67 patients with intrathoracic indications and 24 patients with chest wall defects. Malignancy and infection were the most common indications for reconstruction (P < 0.01). The latissimus dorsi (LD), pectoralis major, and serratus anterior muscle flaps remained the workhorses of reconstruction (LD and pectoralis major: 64% flaps in chest wall reconstruction; LD and serratus anterior: 85% of flaps in intrathoracic indication). Only 12% of patients required mesh. Only 6% of patients with <2 ribs resected required mesh when compared with 24% with 3-4 ribs, and 100% with 5 or more ribs resected (P < 0.01). Increased rib resections required in chest wall reconstruction resulted in a longer hospital stay (P < 0.01). Total comorbidities and complications were related to length of stay only in intrathoracic indication (P < 0.01). Average intubation time was significantly higher in patients undergoing intrathoracic indication (5.51 days) than chest wall reconstruction (0.04 days), P < 0.05. Average hospital stay was significantly higher in patients undergoing intrathoracic indication (23 days) than chest wall reconstruction (12 days), P < 0.05. One-year survival was most poor for intrathoracic indication (59%) versus chest wall reconstruction (83%), P = 0.0048.
Thoracic reconstruction remains a safe and successful intervention that reliably treats complex and challenging problems, allowing more complex thoracic surgery problems to be salvaged.
我们描述了当代用于胸廓重建的第二大皮瓣系列。
对2001年至2013年接受胸廓成形术的患者进行回顾性研究。共确定了91例连续患者。
67例有胸腔内适应证的患者和24例有胸壁缺损的患者接受了胸廓成形术。恶性肿瘤和感染是重建的最常见适应证(P < 0.01)。背阔肌(LD)、胸大肌和前锯肌皮瓣仍然是重建的主要手段(LD和胸大肌:胸壁重建中64%的皮瓣;LD和前锯肌:胸腔内适应证中85%的皮瓣)。只有12%的患者需要使用补片。与切除3 - 4根肋骨的患者中24%以及切除5根或更多肋骨的患者中100%相比,切除肋骨少于2根的患者中只有6%需要使用补片(P < 0.01)。胸壁重建中所需肋骨切除数量增加导致住院时间延长(P < 0.01)。仅在胸腔内适应证中,总合并症和并发症与住院时间相关(P < 0.01)。胸腔内适应证患者的平均插管时间(5.51天)显著高于胸壁重建患者(0.04天),P < 0.05。胸腔内适应证患者的平均住院时间(23天)显著高于胸壁重建患者(12天),P < 0.05。胸腔内适应证患者的1年生存率(59%)与胸壁重建患者(83%)相比最差,P = 0.0048。
胸廓重建仍然是一种安全且成功的干预措施,能够可靠地治疗复杂且具有挑战性的问题,使更复杂的胸外科问题得以挽救。